AI in Telemedicine Platforms 2026: Teladoc, Amwell, Doctolib, Practo

The pandemic-era surge in telemedicine never fully reverted. By 2026 the picture has settled: virtual primary care, virtual urgent care, virtual specialty referrals, and asynchronous messaging are all routine modalities at major US and European health systems and at the dedicated telehealth platforms. The AI layer on top — symptom triage, conversation summarization, claims and coding automation, and clinician-side decision support — has matured alongside.

The cohort of telehealth pure-plays has consolidated meaningfully. Babylon Health went into administration in 2023 (a watershed cautionary tale we will return to). Teladoc absorbed Livongo and then acquired Catapult Health. Amwell rebuilt around its Converge platform. In Europe, Doctolib continues to expand and absorbed Doctena. In India, Practo and Tata 1mg dominate the market. The platform-by-platform 2026 picture is more honest and more useful than the 2021 headlines.

The major platforms and where AI sits#

Teladoc Health — the volume leader in the US — runs an integrated platform across virtual primary care, mental health (BetterHelp), chronic care (Livongo for diabetes and hypertension), and now in-person screening (Catapult). The AI layer covers symptom triage, post-visit summarization, coding/billing automation, member-engagement messaging, and a growing set of clinical-decision support surfaces for the platform’s clinicians. The strategy is less “AI-first” than “AI inside a deep clinical-services business.”

Amwell rebuilt around the Converge platform — a more white-label-friendly stack that health systems use to power their own virtual care brands. Their Carepoint hardware (the kiosk for hospital-room virtual consults) anchors an in-patient telehealth use case that the pure-consumer plays do not address. The Google Cloud partnership underpins much of the AI surface.

MDLive (Evernorth/Cigna), Doctor on Demand (Included Health), and Hims & Hers anchor the rest of the US consumer-virtual-care tier. Each has its own AI surface for intake, triage, and care navigation.

Doctolib is the European heavyweight — booking, video consultation, and a growing AI layer for clinicians. The acquisition of Doctena (2024) extended their footprint across France, Germany, Italy, Austria, Belgium, Luxembourg, and Switzerland. Their physician-side AI assistant for consultation summarization launched broadly through 2025.

KRY/Livi anchors the Nordic and UK virtual-care market with a more clinical model than the US consumer brands. Push Doctor, Babylon-legacy assets, and a handful of NHS-contracted vendors fill out the UK private and public market.

Practo is the Indian incumbent — booking, video consultation, e-pharmacy, diagnostics. Tata 1mg, PharmEasy, Apollo 24/7 sit alongside. The AI layer is heavily Hindi/regional-language and integrates with India’s growing public-health digital infrastructure (ABHA, Ayushman Bharat Digital Mission).

Ping An Good Doctor in China and Halodoc in Indonesia are the regional Asia anchors.

The Babylon Health lesson nobody can avoid#

Babylon Health — once a multi-billion-dollar valuation as an AI-first virtual primary care company — went into administration in 2023, sold its US subsidiary, and its UK assets were eventually wound up. The collapse is a teaching case, not a cautionary footnote.

The honest reading. Babylon’s clinical-AI claims outran the evidence base; their symptom-checker performance versus clinician benchmarks was contested by multiple peer-reviewed evaluations and never fully validated. Their commercial model — full-risk capitation contracts with health systems and the NHS — required a clinical-cost structure that the AI-first model never delivered. When the SPAC public-listing capital ran out and the contracts came up for renewal at worse terms, the business model collapsed.

What survived the post-mortem is the more conservative pattern that the survivors run: AI as an augmentation layer on top of a robust clinical-services operation, not as a replacement for clinician judgement. The companies still standing in 2026 sell virtual clinical care; the AI improves margin and access but does not carry the medical decision alone.

Asynchronous-care AI triage#

Async messaging — patients send a message, AI summarises and triages, clinician responds asynchronously — is one of the cleanest AI use cases in telehealth. Volume is high, urgency is low, the AI’s role is bounded (route the message to the right level of care, draft a clinician response, escalate ambiguous cases).

Major platforms ship this natively. Many health systems build their own on top of Epic MyChart, Athena Communicator, or a custom messaging substrate. The successful pattern: AI surfaces a draft response and a confidence signal to the clinician, who edits and sends. Auto-send without clinician review is rare and increasingly carries explicit regulatory and liability warnings.

Clinician-side AI: summarisation and ambient scribing on the virtual side#

The ambient-scribe wave that took over in-person care (Abridge, DAX Copilot, Suki — covered in our hospital-operations post) has spread into telemedicine. Doctolib’s clinician assistant, Teladoc’s internal tools, Amwell’s Converge AI surfaces, and a handful of third-party scribes (Nabla in Europe is widely deployed in virtual workflows) all generate the encounter note from the video-consultation audio. The integration story is generally easier than in-person because the audio capture is already happening for the call.

Regulatory and reimbursement realities#

US telemedicine reimbursement remained more generous than pre-pandemic but with state-level licensure constraints intact. The DEA’s controlled-substances rules for virtual prescribing were tightened in 2024–2025, ending some of the pure-virtual prescribing models for ADHD and addiction medicine. The cross-state licensure compact movement helped but does not yet match the operating model the largest virtual-care providers want.

EU telehealth is patchwork by member state but trending toward more permissive regimes; the EU AI Act applies to clinical-decision support AI regardless of channel.

India’s telemedicine practice guidelines (2020, expanded since) anchor a clearer regulatory framework than most regional peers, with a fast-growing public-system integration story through ABHA.

Where pdpspectra fits#

We help telehealth platforms and health systems with the operational backbone — integration with EHRs, voice and video pipelines, async-triage AI surfaces, clinician-side tooling, multi-region deployment, and the audit and compliance work that real telehealth at scale requires. See our AI and LLM integration practice.

Related reading#

• Voice AI in clinical documentation
• Healthcare AI playbook: pilot to production
• Hospital management system and telehealth integration

If you are building or operating a telemedicine platform — pure-play, employer-sponsored, or health-system-branded — and want a pragmatic read on the AI investment that pays back, reach out.